MabVax Therapeutics, Inc.
MabVax Therapeutics, Inc. generates its pipeline of antibody based product candidates from patients who have been vaccinated with the proprietary vaccines it has licensed from Memorial Sloan-Kettering Cancer Center (MSKCC). MabVax’s unique approach of surveying the protective immune response from many patients to identify the ideal monoclonal antibody candidate against a specific target on the surface of a cancer cell is a novel next-generation human antibody technology platform.
Its therapeutic vaccines were developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and exclusively licensed to MabVax. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are currently in proof of concept Phase II multi-center clinical trials. A vaccine to address the orphan disease neuroblastoma has completed an initial Phase 1 trial at MSKCC yielding encouraging results.
Forward Looking Statements
Certain statements contained in this blog are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this blog relate to, among other things, the offering and, expected use of proceeds from the offering. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should'" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this blog. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this blog, except as required by applicable law.